Shortlist 2022

• Innovation: How does the entry demonstrate innovation and resourcefulness in response to the pandemic?
• Purpose and Outcomes: Does it achieve its purpose? Does it offer benefits to the audience it was designed for?
• Problem-solving: How does it address the impact of COVID-19? Does it do so in an effective way?
• Competitive Advantage: How does the entry demonstrate going above and beyond or a collaborative approach in a time of crisis?

Innovation in technologies, products, processes, and services for the development and manufacture of active pharmaceutical ingredients (APIs) including, but not limited to, synthesis, characterization, formulation, scale-up, software and database development, bulk manufacturing.

• Innovation: Does the entry introduce a new idea, device, method or Formulation novelty to the market?
• Purpose: Does it achieve its purpose? Does it offer benefits to the audience it was designed for?
• Problem-solving: How does it address the impact of COVID-19? Does it do so in an effective way?
• Competitive Advantage: How does the entry demonstrate going above and beyond or a collaborative approach in a time of crisis?

Entries for this award should relate to launches from the past 18 months (timeline in place for commercialisation). Innovation in technologies, products, processes, and services related to the formulation of drug products including, but not limited to, excipients, finished dose, OTC, novel software and databases, process development, resolving formulation challenges such as solubility/ bioavailability enhancement, drug targeting or controlled release, solving stability issues such as protein aggregation, etc.

• Innovation: Does the entry introduce a new idea, device, method, or novelty to the market?
• Purpose: Does it achieve its purpose? Does it offer benefits to the audience it was designed for?
• Problem-solving: Does it solve a problem? Does it address an issue in an effective way?
• Competitive Advantage: Does it offer a competitive advantage in the market and within its category?

Innovation in technologies, products, processes, and services for the manufacture of solid, semi-solid, parenteral, inhalation, or other dosage drugs including, but not limited to, equipment, manufacturing processes, facilities, process controls, and continuous manufacturing.

• Innovation: Does the entry introduce a new idea, device, method, or novelty to the market?
• Features: Does the product have interesting or important part(s), qualities, abilities, improved attributes?
• Problem-solving: Does it solve a problem? Does it address an issue in an effective way?
• Competitive Advantag: Does it offer a competitive advantage in the market and within its category?

Innovation in technologies, products, solutions, processes, and services related to primary, tertiary and secondary packaging of finished drug forms, routes of administration and drug delivery devices Including, but not limited to, inhalers, auto-injectors, vials, syringes, patches, combination products, tamper-proof packaging, child-safety packaging, labelling, intelligent packaging, and fill-finish.

• Innovation: Does the entry introduce a new idea, device, method or novelty to the market?
• Features & Purpos: Does the product have interesting or important part(s), qualities, abilities, improved attributes?Does it achieve what it was intended to achieve? Does it offer benefits to the audience it was designed for?
• Problem-solving: Does it solve a problem? Does it address an issue in an effective way?
• Competitive Advantag: Does it offer a competitive advantage in the market and within its category?

Innovation in digital technologies, products, processes, initiatives, and services which drive value in pharmaceutical development and improve patient outcomes. Including but not limited to advanced and predictive analytics, Artificial Intelligence, automation, patient-centric solutions for improved experience and adherence, track and trace, remote monitoring, medical devices, and wearables.

• Innovation: Does the entry introduce a new idea, device, method, process, or service to the market?
• Purpose: Does it achieve what it was intended to achieve? Does it offer benefits to the audience it was designed for?
• Problem-solving: Does it solve a problem? Does it address an issue in an effective way?
• Competitive Advantag: Does it offer a competitive advantage in the market and within its category?

Innovation in technologies, products, processes, and services for ensuring the safe handling and tracking of drug substances, raw materials, and finished drug products including, but not limited to, supply chain, audits, temperature-controlled logistics, transport services, track and trace, shipping containers, and distribution channels.

• Innovation: Does the entry introduce a new idea, device, method, or service to the market?
• Purpose: Does it achieve what it was intended to achieve? Does it offer benefits to the audience it was designed for?
• Problem-solving: Does it solve a problem? Does it address an issue in an effective way?
• Competitive Advantag: Does it offer a competitive advantage in the market and within its category?

This award recognizes sustainable development in the Pharmaceutical industry and innovative initiatives for improving outcomes for patients, employees, the environment, and wider community. Including but not limited to, initiatives to minimize environmental impact, waste reduction, energy & utility saving solutions, sustainable and collaborative product development, innovative and sustainable use of resources, social outreach, employee training and mentoring programs, fair employee working policies, diversity and inclusion initiatives.

• Implementation: Does the process of implementing the initiative include all the activities that need to be done to effectuate actual change?
• Achievements: Has the entry/project performed with positive outcomes and high success rates?
• Positive Outcomes to Stakeholder: Did the entry/project provide good results to whoever was involved in or affected by a course of action of the respective company?
• Future: Does the entry/project provide an opportunity for continuity or expansion?

Innovation in technologies, products, processes, and services designed to aid and ensure that bio/pharma companies comply with standards, rules, and guidance documents established by regulatory authorities including, but not limited to, consulting services, development of consortia and industry groups, reference standards, educational programs, and software and IT, technologies, and equipment.

• Innovation: Does the entry introduce a new idea, device, method, or service to the market?
• Process Excellence: Does the product or service offer an improved process, leading to better outcomes and results?
• Problem-solving: Does it solve a problem? Does it address an issue in an effective way?
• Competitive Advantage: Does it offer a competitive advantage in the market and within its category?

C-Suite Executives of SME, Large Pharma/Biopharma or service providers are eligible for nomination. Attributes to be considered include, but are not limited to, financial performance, product performance, global reach, leadership skills, management capability, charitable initiatives, sustainability, regulatory compliance, profitability, vision, marketing, acquisitions, corporate strategy, and financing.

• Dynamism: Is the nominee an exemplary leader with a strong desire to achieve – are they compelling, powerful, progressive?
• Lifetime Achievement: Has the CEO achieved or accomplished sustained growth, driven improved performance, implemented robust strategies, engaged staff and customers in their current role or throughout the course of their career?
• Leadership Qualitie: Has the CEO consistent personal strengths and attributes that makes he or she an extraordinary leader?
• Contribution to the Wider Industry: Is the CEO committed to the development of the pharma industry - be in the form of donating goods, funding, time, market insights business intelligence, new lines of business?